CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
A serious consequence of systemic diffuse large B-cell lymphoma (DLBCL) is secondary central nervous system (CNS) relapse, which occurs in approximately 5% of all patients. Many CNS relapses occur within the first year after completion of frontline treatment and are associated with significantly increased mortality; thus, it is important to tailor frontline treatment to provide prophylaxis against CNS relapse in those patients who are determined to be high-risk. Autologous stem cell transplantation (ASCT) is standard of care for patients with DLBCL who relapse one year or more after first remission, and it has been shown to improve progression-free survival for patients with primary CNS lymphoma. The four-drug BEAM regimen (carmustine, etoposide, cytarabine, and melphalan) is the preferred conditioning regimen for DLBCL patients undergoing ASCT; however, patients with primary CNS lymphoma receive thiotepa plus carmustine as their conditioning regimen due to its better CNS penetration. This study tests the hypothesis that consolidation thiotepa/carmustine ASCT in first complete remission will reduce the risk of CNS relapse in transplant-eligible patients with DLBCL with no prior CNS disease at high risk of secondary CNS recurrence.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Nowo rozpoznany agresywny chłoniak B-komórkowy lub chłoniak powstały z wolnorośniącego nowotworu
- •Pacjent w wysokim ryzyku powrotu choroby w mózgu (np. zaangażowanie nerek, jąder, piersi, szpiku)
- •Wiek 18-75 lat
- •Otrzymuje standardowe leczenie chemioterapią i nie otrzymał więcej niż 2 cykle
- •Zdolność do zrozumienia i podpisania świadomej zgody na uczestnictwo w badaniu
- •Brak postępu choroby po chemioterapii potwierdzone badaniami obrazowymi
- •Ogólny stan zdrowia pozwalający na transplantację (ECOG status ≤ 2)
✗ Disqualifies
- •Transformacja Richtera (szczególny typ progresji chłoniaka)
- •Chłoniak pierwotnie w mózgu (pacjenci z wtórnym zaangażowaniem mózgu są dopuszczeni)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- August 28, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Washington University School of Medicine
St Louis, United States
Trial contact
Amanda F Cashen, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/29/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.